138 related articles for article (PubMed ID: 27728817)
21. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
[TBL] [Abstract][Full Text] [Related]
22. Temperature-Responsive Poly(N-isopropylacrylamide) Modified Gold Nanoparticle-Protein Conjugates for Bioactivity Modulation.
Liu F; Cui Y; Wang L; Wang H; Yuan Y; Pan J; Chen H; Yuan L
ACS Appl Mater Interfaces; 2015 Jun; 7(21):11547-54. PubMed ID: 25948168
[TBL] [Abstract][Full Text] [Related]
23. A gold nanocluster/MIL-100(Fe) bimodal nanovector for the therapy of inflammatory disease through attenuation of Toll-like receptor signaling.
Zhao H; Becharef S; Dumas E; Carn F; Patriarche G; Mura S; Gazeau F; Serre C; Steunou N
Nanoscale; 2024 Jun; 16(25):12037-12049. PubMed ID: 38809107
[TBL] [Abstract][Full Text] [Related]
24. Enhancing endosomal escape for nanoparticle mediated siRNA delivery.
Ma D
Nanoscale; 2014 Jun; 6(12):6415-25. PubMed ID: 24837409
[TBL] [Abstract][Full Text] [Related]
25. Toll-like receptors: promising therapeutic targets for inflammatory diseases.
Achek A; Yesudhas D; Choi S
Arch Pharm Res; 2016 Aug; 39(8):1032-49. PubMed ID: 27515048
[TBL] [Abstract][Full Text] [Related]
26. Unbiased screening of marine sponge extracts for anti-inflammatory agents combined with chemical genomics identifies girolline as an inhibitor of protein synthesis.
Fung SY; Sofiyev V; Schneiderman J; Hirschfeld AF; Victor RE; Woods K; Piotrowski JS; Deshpande R; Li SC; de Voogd NJ; Myers CL; Boone C; Andersen RJ; Turvey SE
ACS Chem Biol; 2014 Jan; 9(1):247-57. PubMed ID: 24117378
[TBL] [Abstract][Full Text] [Related]
27. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization.
Sioud M
J Mol Biol; 2005 May; 348(5):1079-90. PubMed ID: 15854645
[TBL] [Abstract][Full Text] [Related]
28. Nerve growth factor downregulates inflammatory response in human monocytes through TrkA.
Prencipe G; Minnone G; Strippoli R; De Pasquale L; Petrini S; Caiello I; Manni L; De Benedetti F; Bracci-Laudiero L
J Immunol; 2014 Apr; 192(7):3345-54. PubMed ID: 24585880
[TBL] [Abstract][Full Text] [Related]
29. GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation.
Kox M; van Velzen JF; Pompe JC; Hoedemaekers CW; van der Hoeven JG; Pickkers P
Biochem Pharmacol; 2009 Oct; 78(7):863-72. PubMed ID: 19576181
[TBL] [Abstract][Full Text] [Related]
30. Cancer cell-selective promoter recognition accompanies antitumor effect by glucocorticoid receptor-targeted gold nanoparticle.
Sau S; Agarwalla P; Mukherjee S; Bag I; Sreedhar B; Pal-Bhadra M; Patra CR; Banerjee R
Nanoscale; 2014 Jun; 6(12):6745-54. PubMed ID: 24824564
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of immunotropic activity of gold nanocolloid in chickens.
Sembratowicz I; Ognik K
J Trace Elem Med Biol; 2018 May; 47():98-103. PubMed ID: 29544813
[TBL] [Abstract][Full Text] [Related]
32. Iron nanomedicines induce Toll-like receptor activation, cytokine production and complement activation.
Verhoef JJF; de Groot AM; van Moorsel M; Ritsema J; Beztsinna N; Maas C; Schellekens H
Biomaterials; 2017 Mar; 119():68-77. PubMed ID: 28002754
[TBL] [Abstract][Full Text] [Related]
33. Self-assembly of poly-adenine-tailed CpG oligonucleotide-gold nanoparticle nanoconjugates with immunostimulatory activity.
Chen N; Wei M; Sun Y; Li F; Pei H; Li X; Su S; He Y; Wang L; Shi J; Fan C; Huang Q
Small; 2014 Jan; 10(2):368-75. PubMed ID: 23963797
[TBL] [Abstract][Full Text] [Related]
34. Use of gold nanoparticles as crosslink agent to form chitosan nanocapsules: study of the direct interaction in aqueous solutions.
Prado-Gotor R; López-Pérez G; Martín MJ; Cabrera-Escribano F; Franconetti A
J Inorg Biochem; 2014 Jun; 135():77-85. PubMed ID: 24681548
[TBL] [Abstract][Full Text] [Related]
35. TLR based therapeutics.
Dunne A; Marshall NA; Mills KH
Curr Opin Pharmacol; 2011 Aug; 11(4):404-11. PubMed ID: 21501972
[TBL] [Abstract][Full Text] [Related]
36. Oligodeoxynucleotide inhibition of Toll-like receptors 3, 7, 8, and 9 suppresses cytokine production in a human rheumatoid arthritis model.
Sacre S; Lo A; Gregory B; Stephens M; Chamberlain G; Stott P; Brennan F
Eur J Immunol; 2016 Mar; 46(3):772-81. PubMed ID: 26593270
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and conjugation of Sr
Homayoni H; Ma L; Zhang J; Sahi SK; Rashidi LH; Bui B; Chen W
Photodiagnosis Photodyn Ther; 2016 Dec; 16():90-99. PubMed ID: 27594671
[TBL] [Abstract][Full Text] [Related]
38. Rational design of peptide derivatives for inhibition of MyD88-mediated toll-like receptor signaling in human peripheral blood mononuclear cells and epithelial cells exposed to Francisella tularensis.
Ryan DA; Degardin M; Alam S; Kissner TL; Hale M; Cameron MD; Rebek M; Ajami D; Saikh KU; Rebek J
Chem Biol Drug Des; 2017 Dec; 90(6):1190-1205. PubMed ID: 28599094
[TBL] [Abstract][Full Text] [Related]
39. TLR activation pathways in HIV-1-exposed seronegative individuals.
Biasin M; Piacentini L; Lo Caputo S; Naddeo V; Pierotti P; Borelli M; Trabattoni D; Mazzotta F; Shearer GM; Clerici M
J Immunol; 2010 Mar; 184(5):2710-7. PubMed ID: 20124101
[TBL] [Abstract][Full Text] [Related]
40. Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders.
Fukata M; Vamadevan AS; Abreu MT
Semin Immunol; 2009 Aug; 21(4):242-53. PubMed ID: 19748439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
